Related Experiment Video
Updated: Jun 24, 2026
14:18
Dioscin Mediated IgA Nephropathy Alleviation by Inhibiting B Cell Activation In Vivo and Decreasing Galactose-Deficient IgA1 Production In Vitro
Published on: October 13, 2023
Ganoderic acid DM: anti-androgenic osteoclastogenesis inhibitor
Jie Liu1, Jun Shiono, Kuniyoshi Shimizu
1Department of Forest and Forest Products Science, Faculty of Agriculture, Kyushu University, Fukuoka, Japan.
Bioorganic & Medicinal Chemistry Letters
|March 18, 2009
Summary
Ganoderic acid DM from Ganoderma lucidum inhibits prostate cancer cell growth and bone metastasis. This compound shows 5alpha-reductase inhibitory and androgen receptor binding activity, offering potential therapeutic benefits.
Area of Science:
- Oncology
- Pharmacology
- Biochemistry
Background:
- Prostate cancer is a prevalent malignancy in Western countries, frequently metastasizing to bone.
- Bone metastasis in prostate cancer contributes to significant morbidity.
- The androgen receptor (AR) signaling pathway is crucial in prostate cancer progression.
Purpose of the Study:
- To investigate the effects of Ganoderic acid DM on prostate cancer cell growth.
- To evaluate the potential of Ganoderic acid DM in inhibiting osteoclastogenesis, a key process in bone metastasis.
- To explore the mechanism of action, including 5alpha-reductase inhibition and AR binding.
Main Methods:
- Ganoderic acid DM was isolated from Ganoderma lucidum ethanol extracts.
- Prostate cancer cell lines were used to assess cell growth inhibition.
- Osteoclast differentiation and activity were studied to evaluate effects on osteoclastogenesis.
- In vitro assays were performed to determine 5alpha-reductase inhibitory and AR binding activities.
Main Results:
- Ganoderic acid DM demonstrated significant inhibition of prostate cancer cell proliferation.
- The compound effectively blocked osteoclastogenesis, reducing bone resorption.
- Ganoderic acid DM exhibited 5alpha-reductase inhibitory activity and bound to the androgen receptor.
Conclusions:
- Ganoderic acid DM possesses anti-prostate cancer properties, including inhibition of cell growth and osteoclastogenesis.
- Its dual activity on 5alpha-reductase and androgen receptor suggests a potential therapeutic role in managing prostate cancer and its bone metastases.
